Currently, several therapeutic strategies are available for managing diabetic wounds, including aggressive debridement, surgical angiogenesis, antibacterial therapy, and bioengineered alternative tissue products 7,8
[8] Retatrutide is the triple-agonist expression of that trajectory, engineered as one peptide that hits GIP, GLP-1, and glucagon receptors simultaneously
Our practice was founded and is led by Stefanie Drozd, MSN, APRN, a board-certified nurse practitioner, and every location follows the same NP-led safety standards
This G protein-coupled receptor is primarily expressed on somatotroph cells in the anterior pituitary gland